Aashish Dua, MD
Interventional Cardiology · Monroeville, PANPI 1114961018
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $158,905 of the $188,824 with a category attached, or 84.2%. 34 manufacturers reported payments, led by Johnson & Johnson at 50.1% of the total. Reporting peaked in 2022 at $47,127 and has fallen 66.1% since, to $15,977 in 2025. Among interventional cardiology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 484 payments — averaging $390.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$95K
- AstraZeneca$43K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$27K
- Novartis$7K
- Angiodynamics, Inc.$5K
- Penumbra, Inc.$2K
- plus $10K from 28 others
Across 1 payment — averaging $2040.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bard Peripheral Vascular, Inc.$2K
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$158,90584%
- Travel & lodging$12,6367%
- Food & beverage$16,9539%
- Education$290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 83 | $94,683 |
| AstraZeneca | 59 | $42,587 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 41 | $26,830 |
| Novartis | 20 | $7,111 |
| Angiodynamics, Inc. | 28 | $5,494 |
| Penumbra, Inc. | 5 | $2,078 |
| Medtronic(2 entities) | 53 | $2,047 |
| Edwards Lifesciences | 22 | $1,384 |
| Boston Scientific | 30 | $1,206 |
| Inari Medical, Inc. | 4 | $834 |
| Shockwave Medical, Inc | 13 | $782 |
| Abiomed | 14 | $569 |
| Abbott | 10 | $527 |
| Cardiovascular Systems Inc. | 21 | $507 |
| Heartflow, Inc. | 6 | $402 |
| Pfizer | 18 | $373 |
| E.r. Squibb & Sons, L.L.C. | 10 | $169 |
| Terumo Medical Corporation | 1 | $141 |
| Boehringer Ingelheim | 5 | $118 |
| Amarin Pharma, Inc. | 4 | $115 |
| Scpharmaceuticals Inc. | 6 | $112 |
| Bayer | 5 | $109 |
| Amgen | 7 | $107 |
| Cardiva Medical, Inc. | 3 | $101 |
| Cagent Vascular Inc | 1 | $87 |
| Novo Nordisk | 4 | $80 |
| Chiesi USA, Inc. | 2 | $55 |
| Daiichi Sankyo Inc. | 2 | $53 |
| Actelion Pharmaceuticals US, Inc. | 2 | $45 |
| Kestra Medical Technology Services, Inc. | 1 | $30 |
| Impulse Dynamics (USA) Inc. | 1 | $30 |
| Teleflex LLC | 1 | $22 |
| Acist Medical Systems, Inc. | 1 | $20 |
| GSK | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$93,204
- FARXIGA$33,026
- LifeVest$25,377
- LOKELMA$8,613
- ENTRESTO$6,844
- AngioVac$2,956
- AlphaVac$2,168
- Indigo System$2,061
- FLOWTRIEVER CATHETER, S$1,103
- CT THROMBECTOMY SYSTEM KIT$474
- IN.PACT Admiral$438
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$423
- Impella$385
- SAPIEN 3 Ultra RESILIA$329
- FFRct$254
- XACT$162
- COROFLOW$153
- OPTICROSS$148
- Edwards SAPIEN 3 Transcatheter Heart Valve$147
- METACROSS OTW$141
How this compares
$188,824 in reported general payments places this provider in the 90th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 232 | $262,720 |
| XareltoRivaroxaban | 180 | $188,359 |
| FarxigaDapagliflozin Propanediol | 85 | $77,067 |
| EntrestoSacubitril/Valsartan | 50 | $74,013 |
| BrilintaTicagrelor | 95 | $64,389 |
| Repatha SureclickEvolocumab | 21 | $19,966 |
| JardianceEmpagliflozin | 20 | $19,190 |
| MultaqDronedarone Hcl | 19 | $18,314 |
| DapagliflozinDapagliflozin Propanediol | 27 | $15,940 |
| Ranolazine ErRanolazine | 94 | $8,091 |
| Bumetanide | 166 | $4,831 |
| Metoprolol Succinate | 286 | $4,086 |
| Atorvastatin Calcium | 362 | $3,756 |
| ClopidogrelClopidogrel Bisulfate | 370 | $3,362 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 57 | $2,619 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $373 | $262,720232 claims |
| Johnson & JohnsonXarelto | $94,683 | $188,359180 claims |
| AstraZenecaFarxiga, Brilinta | $42,587 | $141,457180 claims |
| NovartisEntresto | $7,111 | $74,01350 claims |
| Boehringer IngelheimJardiance | $118 | $19,19020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Monroeville
- Amber MakaniMonroeville$78K
- Nishant SethiScranton$1.3M
- Matthew BeckerErie$1M
- William GrayWynnewood$753K
- Jon GeorgePhiladelphia$637K
- Shailendra SinghAllentown$470K
- Sanjog KalraPhiladelphia$444K
- James HarveyChambersburg$442K
- Taisei KobayashiPhiladelphia$384K
- Antonis PratsosBroomall$377K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.